Monitor the next 8-K or 10-Q for the outcome of the trial period ending December 31, 2026, which could indicate a change in executive compensation structure.
Price Chart
Executive Summary
Cingulate Inc. filed an 8-K to disclose an amendment to the employment agreement of its Chief Medical Officer, Matthew N. Brams, extending the trial period for his full-time employment from September 30, 2026 to December 31, 2026. The base salary remains $400,000 per year through the trial period, after which the CEO may return the executive to a part-time role at a lower salary. This is a routine administrative amendment with no material financial impact.
Key Facts
- Matthew N. Brams, Executive Vice President and Chief Medical Officer, had his trial period for full-time employment extended from September 30, 2026 to December 31, 2026.
- Annual base salary remains $400,000 through the trial period.
- After the trial period, the CEO may decide to keep the executive full-time or return to part-time at a lower salary.
- No departure, resignation, or termination occurred; no new officer appointed.
Financial Impact
No material financial impact; compensation terms unchanged through trial period extension.
Risk Factors
- Potential future reduction in executive commitment if returned to part-time role.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045527 |
| Exhibit: ex10-1.htm | 0001493152-26-045527 |
| Document: 0001493152-26-045527-index-headers.html | 0001493152-26-045527 |
| Document: 0001493152-26-045527-index.html | 0001493152-26-045527 |
| Document: 0001493152-26-045527.txt | 0001493152-26-045527 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | 8-K | $4.75 | awaiting T+60 | — | $4.98 (+4.84%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.15 | awaiting T+60 | — | $4.98 (−3.21%) |
Aug 13, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $4.98 (−0.20%) |
Jul 14, 2026 14w ago | 8-K | $4.71 $4.87 | ▲ +3.40% | ▲ +0.02% | $4.98 (+5.73%) |
Jun 16, 2026 18w ago | 8-K | $4.74 $5.17 | ▲ +9.07% | ▲ +8.07% | $4.98 (+5.06%) |
Jun 8, 2026 19w ago | Insider Cluster | $4.65 $5.15 | ▲ +10.75% | ▲ +6.94% | $4.98 (+7.10%) |
Mar 25, 2026 30w ago | EFFECT | $6.36 $4.97 | ▼ −21.86% | ▼ −35.31% | $4.98 (−21.70%) |
Mar 23, 2026 31w ago | S-3/A | $6.93 $5.12 | ▲ +26.12% | ▲ +39.18% | $4.98 (+28.14%) |
Mar 18, 2026 31w ago | DEFA14A | $7.51 $4.93 | ▼ −34.35% | ▼ −48.70% | $4.98 (−33.69%) |
Mar 18, 2026 31w ago | 8-K | $8.04 $5.09 | ▼ −36.69% | ▼ −48.22% | $4.98 (−38.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers